Risk of new-onset heart failure in patients using sitagliptin: A population-based cohort study

Diabetic Medicine

Volumn 33, Issue 5, 2016, Pages 621-630

  Eurich, D T ^a   Weir, D L ^b   Simpson, S H ^a   Senthilselvan, A ^a   Mcalister, F A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEGLITINIDE; METFORMIN; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; PRAMLINTIDE; PRESCRIPTION DRUG; SITAGLIPTIN; SULFONYLUREA; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGE; ANTICOAGULANT THERAPY; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC PATIENT; DIURETIC THERAPY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION BASED CASE CONTROL STUDY; SEX; CASE CONTROL STUDY; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; ELECTRONIC HEALTH RECORD; FOLLOW UP; HEALTH INSURANCE; HOSPITAL READMISSION; HOSPITALIZATION; PROPENSITY SCORE; RISK; STATISTICAL MODEL; UNITED STATES;

ACUTE CORONARY SYNDROME; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; INSURANCE, HEALTH; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT READMISSION; PROPENSITY SCORE; RISK; SITAGLIPTIN PHOSPHATE; UNITED STATES;

EID: 84940062320     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12867     Document Type: Article

References (37)

1. Amato L, Paolisso G, Cacciatore F, Ferrara N, Ferrara P, Canonico Set al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 1997; 23: 213-218.
2. Fonarow GC. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones. Am Heart J 2004; 148: 551-558.
3. Havranek EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL, Krumholz HM. Spectrum of heart failure in older patients: results from the National Heart Failure project. Am Heart J 2002; 143: 412-417.
4. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003; 26: 2433-2441.
5. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GLet al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. NEJM 2013; 369: 1327-1335.
6. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg Bet al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. NEJM 2013; 369: 1317-1326.
7. Sanon VP, Sanon S, Pham SV, Chilton R. Play of Chance Versus Concerns Regarding Dipeptidyl Peptidase-4 Inhibitors: Heart Failure and Diabetes. Clin Diabetes 2014; 32: 121-126.
8. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014; 24: 689-697.
9. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015; 3: 356-366.
10. Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin Use in Patients With Diabetes and Heart Failure: A Population-Based Retrospective Cohort Study. JACC Heart Failure 2014; 2: 573-682.
11. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim Pet al. Heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR - TIMI 53 Randomized Trial. Circulation 2014; 130: 1579-1588.
12. Yu OH, Filion KB, Azoulay L, Patenaude V, Majdan A, Suissa S. Incretin-Based Drugs and the Risk of Congestive Heart Failure. Diabetes Care 2015; 38: 227-284.
13. Segal JB, Dy SM, Millman EA, Herbert R, Bass EB, Wu A. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy. Clin Ther 2007; 29: 1784-1794.
14. Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007; 27: 1102-1110.
15. Duh MS, Gosselin A, Luo R, Lohoues H, Lewis BE, Crawley JA. Impact of compliance with proton pump inhibitors on NSAID treatment. Am J Manag Care 2009; 15: 681-688.
16. Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Ther 2009; 31: 623-631.
17. Report from the National Diabetes Surveillance System: Diabetes in Canada 2009. Public Health Agency of Canada. Available at http://www.phac-aspc.gc.ca/publicat/2009/ndssdic-snsddac-09/index-eng.php) Last accessed 10 September 2014.
18. O'Connor RE, Brady W, Brooks SC, Diercks D, Egan J, Ghaemmaghami Cet al. Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122: S787-817.
19. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepid Drug Saf 2007; 16: 711-725.
20. Abdelmoneim AS, Eurich DT, Gamble JM, Johnson JA, Seubert JM, Qiu Wet al. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study. Diabetes Obes Metab 2014; 16: 22-29.
21. Goff DCJr, Pandey DK, Chan FA, Ortiz C, Nichaman MZ. Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Int Med 2000; 160: 197-202.
22. Hammill BG, Curtis LH, Whellan DJ, Hernandez AF. A comparison of algorithms for identifying incident and prevalent heart failure patients in administrative databases. Circulation 2007; 115: E552-E552.
23. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. Am J Epid 1994; 140: 1016-1019.
24. Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epid 2002; 12: 462-468.
25. Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 2013; 346: f2267.
26. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Method 2005; 5: 5-6.
27. Richardson DB. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004; 61: e59.
28. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298: 2634-2643.
29. Penson DF, Stoddard ML, Pasta DJ, Lubeck DP, Flanders SC, Litwin MS. The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. J Clin Epid 2001; 54: 350-358.
30. Huberman M, Langholz B. Application of the missing-indicator method in matched case-control studies with incomplete data. Am J Epid 1999; 150: 1340-1345.
31. John Hopkins university. The John Hopkins ACG System. 2012. Available at: http://www.acg.jhsph.org/. Last accessed 23 May 2015.
32. Sternberg SA, Bentur N, Abrams C, Spalter T, Karpati T, Lemberger Jet al. Identifying frail older people using predictive modeling. Am J Manag Care 2012; 18: e392-397.
33. Austin PC, Shah BR, Newman A, Anderson GM. Using the Johns Hopkins' Aggregated Diagnosis Groups (ADGs) to predict 1-year mortality in population-based cohorts of patients with diabetes in Ontario, Canada. Diabet Med 2011; 29: 1134-1141.
34. Rassen JA, Shelat AA, Franklin JM, Glynn RJ, Solomon DH, Schneeweiss S. Matching by propensity score in cohort studies with three treatment groups. Epidemiology 2013; 24: 401-409.
35. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33: 187-215.
36. Lavie CJ, Ventura HO. Analyzing the weight of evidence on the obesity paradox and heart failure-is there a limit to the madness?Cong Heart Heart Fail 2013; 19: 158-159.
37. Moin T, Li J, Duru OK, Ettner S, Turk N, Keckhafer Aet al. Metformin Prescription for Insured Adults With Prediabetes From 2010 to 2012A Retrospective Cohort StudyMetformin Prescription for Insured Adults With Prediabetes. Ann Intern Med 2015; 162: 542-548.